Lapatinib
From Proteopedia
(Difference between revisions)
| Line 55: | Line 55: | ||
! Sorafenib (Nexavar) | ! Sorafenib (Nexavar) | ||
|} | |} | ||
| + | <references/> | ||
Revision as of 07:56, 6 December 2010
Pharmacokinetics
| Tyrosine Kinase Inhibitor Pharmacokinetics [1] | |||||
|---|---|---|---|---|---|
| Parameter | Lapatinib (Tykerb) | Sunitinib (Sutent) | Sorafenib (Nexavar) | ||
| Tmax (hr) | 4 | Sunitinib (Sutent) | Sorafenib (Nexavar) | ||
| Cmax (ng/ml) | 115 | Sunitinib (Sutent) | Sorafenib (Nexavar) | ||
| Bioavailability (%) | Lapatinib (Tykerb) | Sunitinib (Sutent) | Sorafenib (Nexavar) | ||
| Protein Binding (%) | Lapatinib (Tykerb) | Sunitinib (Sutent) | Sorafenib (Nexavar) | ||
| T1/2 (hr) | 9.6 | Sunitinib (Sutent) | Sorafenib (Nexavar) | ||
| AUC (ng/ml/hr) | 1429 | Sunitinib (Sutent) | Sorafenib (Nexavar) | ||
| IC50 (nM) | Lapatinib (Tykerb) | Sunitinib (Sutent) | Sorafenib (Nexavar) | ||
| Dosage (mg) | 100 | Sunitinib (Sutent) | Sorafenib (Nexavar) | ||
| Metabolism | Lapatinib (Tykerb) | Sunitinib (Sutent) | Sorafenib (Nexavar) | ||
- ↑ PMC:2679105
